California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis ...

Three-dimensional (3D) printing is a 20-year-old technology whose time finally seems to have arrived. Interest in the equipment rose sharply last year; in 2012, the market for 3D products reached $777 ...

On this week's Business of Biotech, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at ...